Debbie Rigby rounds up the latest in research news
An updated meta-analysis and meta-regression of 40 interventional trials has concluded that supplementation with EPA and DHA is an effective lifestyle strategy for CVD prevention, and the protective effect probably increases with dosage. Supplementation was associated with a 13% reduced risk of MI (NNT 272), 10% reduced risk of CHD events (NNT 192), 35% reduced risk of fatal MI (NNT 128), and 9% reduced risk of CHD mortality (NNT 431).
Mayo Clinic Proceedings 2020.
A Cochrane Review has concluded that it is unlikely that magnesium supplementation provides clinically meaningful cramp prophylaxis to older adults experiencing skeletal muscle cramps. For idiopathic cramps no statistically significant difference was found at four weeks in measures of cramp intensity or cramp duration. Overall, oral magnesium was associated with mostly gastrointestinal adverse events (e.g. diarrhoea).
Cochrane Database of Systematic Reviews 2020, Issue 9.
This prospective analysis of 204 689 participants free of diabetes in the Nurses’ Health Study (NHS), NHS II and Health Professionals Follow-up Study (HPFS) showed regular use of PPIs was associated with a 24% higher risk of type 2 diabetes. The risk increased with longer duration of use. PPIs have a major impact on gut microbiome which, in turn, may increase the risk of type 2 diabetes.
The first step of migraine management is addressing lifestyle triggers and comorbidities. Acute migraine treatments (paracetamol, aspirin, NSAIDs, antiemetics, triptans) primarily manage the headache component and should be started as early as possible in the migraine attack. Prophylactic therapy is indicated in patients with three or more severe headache days per month causing functional impairment that are not consistently responsive to acute treatments.
Aust Prescr 2020;43:148-51.